Current Approach to Diagnosis and Management of Chronic Lymphocytic Leukemia
- Translocation t(1;6)(p35.3;p25.2): a new recurrent aberration inâ€˜unmutatedâ€™B-CLL. Michaux, L; Wlodarska, I; Rack, K; Stul, M; Criel, A; Maerevoet, M; Marichal, S; Demuynck, H; Mineur, P; Samani, K Kargar; Hoof, A Van; Ferrant, A; Marynen, P; Hagemeijer, A // Leukemia (08876924);Jan2005, Vol. 19 Issue 1, p77
Although reciprocal chromosomal translocations are not typical for B-cell chronic lymphocytic leukemia (B-CLL), we identified the novel t(1;6)(p35.3;p25.2) in eight patients with this disorder. Interestingly, all cases showed lack of somatically mutated IgVH. Clinical, morphological,...
- Proliferation centers in chronic lymphocytic leukemia: correlation with cytogenetic and clinicobiological features in consecutive patients analyzed on tissue microarrays. Ciccone, M; Agostinelli, C; Rigolin, G M; Piccaluga, P P; Cavazzini, F; Righi, S; Sista, M T; Sofritti, O; Rizzotto, L; Sabattini, E; Fioritoni, G; Falorio, S; Stelitano, C; Olivieri, A; Attolico, I; Brugiatelli, M; Zinzani, P L; Saccenti, E; Capello, D; Negrini, M // Leukemia (08876924);Mar2012, Vol. 26 Issue 3, p499
To better define the significance of proliferation centers (PCs), the morphological hallmark of chronic lymphocytic leukemia (CLL), lymph node biopsies taken from 183 patients were submitted to histopathologic and fluorescence in situ hybridization (FISH) studies using a 5-probe panel on tissue...
- Novel Monoclonal Antibodies for the Treatment of Chronic Lymphocytic Leukemia. Robak, Tadeusz // Current Cancer Drug Targets;Mar2008, Vol. 8 Issue 2, p156
For many years, alkylating agents and purine nucleoside analogs (PNA) have been considered the drug of choice for treatment of chronic lymphocytic leukemia (CLL). More recently the introduction of monoclonal antibodies (mAb), especially rituximab directed against CD20 and alemtuzumab directed...
- The complement system in chronic B cell lymphoproliferative disorders. Lugassy, G; Schlesinger, M // Leukemia (08876924);Apr98, Vol. 12 Issue 4, p636
Focuses on the complement system in chronic lymphocyte leukemia (CLL), a B cell lymphoproliferative disorder. Correlation between hypocomplementemia lymphocyte activation and differentiation stages; Evidence supporting a hereditary background for hypocomplementemia in CLL; Role of complement...
- Prognostic impact and landscape of NOTCH1 mutations in chronic lymphocytic leukemia (CLL): a study on 852 patients. Weissmann, S; Roller, A; Jeromin, S; Hernández, M; Abáigar, M; Hernández-Rivas, J M; Grossmann, V; Haferlach, C; Kern, W; Haferlach, T; Schnittger, S; Kohlmann, A // Leukemia (08876924);Dec2013, Vol. 27 Issue 12, p2393
A letter to the editor is presented that discusses NOTCH1 mutations in chronic lymphocytic leukemia.
- 2012 American Society of Clinical Oncology Annual Meeting: Experimental agent may help older people with chronic leukemia. // Biomedical Market Newsletter;5/25/2012, Vol. 21, p1
The article offers information on a clinical trial study which reveals that the drug ibrutinib has the potential to treat elderly patients with chronic lymphocytic leukemia.
- United Kingdom : GSK and Genmab announce positive interim result for phase III study of ofatumumab as maintenance therapy for relapsed CLL. // TendersInfo News;8/1/2014, p1
The article reports on the announcement by pharmaceutical company GSK and biotechnology company Genmab on August 1, 2014 of positive interim result for phase III study of ofatumumab as maintenance therapy for relapsed chronic lymphocytic leukaemia (CLL).
- The prognostic impact of minimal residual disease assessment after stem cell transplantation for chronic lymphocytic leukemia: is achievement of molecular remission worthwhile? Dreger, P.; Ritgen, M.; Böttcher, S.; Schmitz, N.; Kneba, M. // Leukemia (08876924);Jul2005, Vol. 19 Issue 7, p1135
Comments on the prognostic impact of minimal residual disease assessment after stem cell transplantation on chronic lymphocytic leukemia. Methods of detecting and measuring chronic lymphocytic leukemia cells; Measurement of minimal residual chronic lymphocytic leukemia disease; Treatment...
- Acute tumour lysis syndrome after oral fludarabine in a patient with chronic lymphocytic leukaemia. Ramachandran, Akila; Majumdar, Gautam // Hematology Journal;2004, Vol. 5 Issue 6, p528
Acute tumour lysis syndrome (TLS) is a very rare complication of cytotoxic therapy in patients with chronic lymphocytic leukaemia (CLL). We report a patient with CLL who developed tumour lysis syndrome twice after oral fludarabine therapy. Both times TLS developed more than 2 weeks after the...